Latest Breaking News On - Novartis pharms - Page 5 : comparemela.com

Federal Circuit Backtracks On Negative Claim Limitations In Fingolimod Patent - Patent

In a reversal of fortunes, the Federal Circuit entertained a petition for rehearing from the losing side of a decision on Jan. 3, 2022 in this case, and has now decided that the.

Novartis Pharms. Corp. V. Accord Healthcare, Inc. - Gilenya速 (Fingolimod Hcl) | Robins Kaplan LLP

Case Name: Novartis Pharms. Corp. v. Accord Healthcare, Inc., No. 2021-1070, 2022 WL 2204163 (Fed. Cir. June 21, 2022) (Circuit Judges Moore, Linn, and Hughes presiding; Opinion by.

Prosecution Pointer 339 - Patent - United States

Here is a link to the various USPTO Patent Center submission options. It also identifies filings that are available with DOCX.

Federal Circuit analyzes requirement for written description of negative claim limitations | Bryan Cave Leighton Paisner

Federal Circuit Reconsiders Written Description Support For Negative Limitation - Patent

The original Federal Circuit decision in Novartis Pharms. Corp. v. Accord Healthcare, Inc. was on the list of "written description" cases I covered in several conference programs this spring.